Powder: | Yes |
---|---|
Customized: | Non-Customized |
Certification: | GMP, HSE, ISO 9001, USP, BP |
Suitable for: | Elderly, Children, Adult |
State: | Solid |
Purity: | >99% |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
A series of clinical studies have demonstrated that inhibition of IL-6 signaling by tocilizumab is highly effective in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, giant lymph node hyperplasia, and Crohn's disease. In these diseases, tocilizumab slows down the clinical manifestations of inflammation and returns acute phase protein levels to normal. tochemicalbookocilizumab is well tolerated whether administered as a single agent or in combination (e.g., with methotrexate). tocilizumab significantly reduces the number of invading capillaries in tumors. Otherwise, tocilizumab had no effect on the rate of mitosis and apoptosis of tumor cells.
Product Name | TocilizuMab |
Synonyms | TocilizuMab;Actemra;Actemra 200;anti-IL-6R Tocilizumab;Atlizumab;R 1569;RoActemra;Tocilizumab,Atlizumab |
MOQ | 1kg |
CAS | 375823-41-9 |
Appearance | white |
Molecular Formula | C14H12O3 |
Molecular Weight | 0 |
Assay | >99% |
Application | For research purpose only |
Packing | 25kg/drum |
Storage | Store in a well-closed,light-resistant container |
Remarks | NA |
Custom synthesis | Available |
Suppliers with verified business licenses